FDA Panel Weighs Guidelines For Human Clinical Trials Involving Treatments From Embryonic Stem Cells
Because of the potential risks involved in human embryonic stem cells, data on the effectiveness of treatments using them “may need to be particularly strong,” Steven Bauer, chief of FDA’s cell and tissue therapy branch, said in a presentation to the FDA advisory
More: continued here